This month, Small Cap Nation's Jane King sat down with Crystal Research Associates' CEO Jeffrey Kraws to discuss the current state and future outlook of our research company. The interview, available below, also included a discussion of important trends facing the corporate research and communications industry as well as factors impacting some of the industries we serve (e.g., healthcare).

Tomorrow kicks off one of the year’s largest oncology conferences: the American Society of Clinical Oncology (ASCO) Annual Meeting, held this year over June 3-7 at McCormick Place in Chicago. With over 30,000 attendees and hundreds of presenting companies, the conference will undoubtedly include important clinical data announcements from the likes of Pfizer, Genentech, and others as well as give some smaller firms the opportunity to introduce novel oncology candidates. Amid the presentations and exhibitions, one topic in particular is expected to stand out: the costs of cancer care.

“Building a profile and becoming ‘known’ is a critical part of raising money…” — Erin Righetti, partnering360®

Healthcare conferences are in full swing this week in San Francisco, with attendees from companies large and small making the circuit at J.P. Morgan’s Annual Healthcare Conference, the EBD Group’s annual Biotech Showcase™, the StartUp Health Festival, and many others. From corporate presentations to strategic one-on-one meetings and even impromptu run-ins, networking opportunities abound and it is important for CEOs to be able to quickly, concisely, and effectively pitch their company to potential investors and/or partners.

In just six months, drug companies have spent $221 billion buying each other, with a lot of recent mergers being between biotech firms. So what is driving the deals? Business television show Arise Xchange sits down with Jeff Kraws, Cofounder and CEO of Crystal Research Associates, to discuss. 

Runtime: 3:38 minutes

In the wake of a new report from the British government stating that antibiotic-resistant infections could kill 10 million people each year by the year 2050, senior pharmaceutical analyst Jeff Kraws of Crystal Research Associates sits down with host Akhtar Khan of Arise Xchange to discuss the report's projections and impacts of increasing drug resistance on the pharmaceutical industry and on consumers.

On Tuesday, October 14, Crystal Research Associates' senior pharmaceutical analyst and chief executive officer, Jeff Kraws, sat down with Andrew Schmertz, host of Arise TV's Xchange program, to discuss public and private efforts at curbing the Ebola outbreak.

The segment below is an excerpt from ARISE TV's Arise XChange news program, aired live from 5 pm to 5:30 pm on Wednesday, April 30. Host Andrew Schmertz and Crystal Research CEO and Senior Pharmaceutical Analyst Jeffrey Kraws discuss recent M&A activity in the pharmaceutical industry, including Pfizer's proposed buyout of AstraZeneca.

Clip length: 5:34

If you missed the "Extending Life and Limb" workshop on regenerative medicine held last week at the OneMedForum conference in San Francisco, you can watch the full panel discussion on YouTube at the link below.

If you are in San Francisco today for the JP Morgan Healthcare Conference, the Biotech Showcase, or the 7th annual OneMedForum, we welcome you to stop by the Westin San Francisco on Market Street to visit our booth and hear Crystal Research CEO Jeffrey Kraws speak on regenerative medicine.

Crystal Research Associates is pleased to announce today that we have officially launched our mobile app and our new website. Take a look around at some of the changes...it is now easier than ever to sign up for research notifications and even start a discussion with us about your business's strategic needs. We have also recently expanded our line of products and services, which is now reflected throughout the site.